0001179110-20-000665.txt : 20200117 0001179110-20-000665.hdr.sgml : 20200117 20200117211547 ACCESSION NUMBER: 0001179110-20-000665 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200116 FILED AS OF DATE: 20200117 DATE AS OF CHANGE: 20200117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chapman Steven Leonard CENTRAL INDEX KEY: 0001711968 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37478 FILM NUMBER: 20534893 MAIL ADDRESS: STREET 1: 201 INDUSTRIAL ROAD, SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Natera, Inc. CENTRAL INDEX KEY: 0001604821 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 010894487 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 INDUSTRIAL ROAD STREET 2: SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-249-9090 MAIL ADDRESS: STREET 1: 201 INDUSTRIAL ROAD STREET 2: SUITE 410 CITY: SAN CARLOS STATE: CA ZIP: 94070 4 1 edgar.xml FORM 4 - X0306 4 2020-01-16 0 0001604821 Natera, Inc. NTRA 0001711968 Chapman Steven Leonard C/O NATERA, INC., 201 INDUSTRIAL ROAD SUITE 410 SAN CARLOS CA 94070 1 1 0 0 Chief Executive Officer Common Stock 2020-01-16 4 M 0 9818 9.59 A 32540 D Common Stock 2020-01-16 4 M 0 15641 10.41 A 48181 D Common Stock 2020-01-16 4 M 0 7292 10.73 A 55473 D Common Stock 2020-01-16 4 M 0 21367 9.29 A 76840 D Common Stock 2020-01-16 4 M 0 25000 13.01 A 101840 D Common Stock 2020-01-16 4 M 0 37500 13.01 A 139340 D Common Stock 2020-01-16 4 S 0 116618 35.00 D 22722 D Common Stock 2020-01-16 4 S 0 22722 35.00 D 0 D Stock Option (right to buy) 9.59 2020-01-16 4 M 0 9818 0 D 2026-04-07 Common Stock 9818 4376 D Stock Option (right to buy) 10.41 2020-01-16 4 M 0 15641 0 D 2027-06-08 Common Stock 15641 33516 D Stock Option (right to buy) 10.73 2020-01-16 4 M 0 7292 0 D 2027-07-13 Common Stock 7292 15625 D Stock Option (right to buy) 9.29 2020-01-16 4 M 0 21367 0 D 2028-03-08 Common Stock 21367 82418 D Stock Option (right to buy) 13.01 2020-01-16 4 M 0 25000 0 D 2029-01-10 Common Stock 25000 75000 D Stock Option (right to buy) 13.01 2020-01-16 4 M 0 37500 0 D 2029-01-11 Common Stock 37500 162500 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2019. The option shares vest over four years. 25% of the option shares vest and become exercisable on April 1, 2017 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vest and become exercisable on March 21, 2018 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vest and become exercisable on March 12, 2018 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vest and become exercisable on March 9, 2019 and the remaining shares vest in 36 equal monthly installments thereafter. The option shares vest over four years. 25% of the option shares vest and become exercisable on January 2, 2020 and the remaining shares vest in 36 equal monthly installments thereafter. This option becomes exercisable, if at all, upon the Reporting Person achieving certain milestones relating to a combination of the passage of time and the Reporting Person achieving certain milestones relating to the Issuer's stock price, based on the average closing price per share of the Issuer's common stock for a calendar month, calculated as of the last day of such calendar month. The first milestone is the Issuer's stock price equaling or exceeding the quotient of (i) $2,000,000,000 and (ii) the Issuer's outstanding shares as most recently reported on the Issuer's Form 10-Q or Form 10-K (the "Capitalization"). The second milestone is the Issuer's stock price equaling or exceeding the quotient of (i) $3,000,000,000 and (ii) the Capitalization (the "Performance Vesting Conditions"). As of September 19, 2019, the Company's Board of Director determined the performance criteria had been met with respect to 37,500 shares. /s/ Tami Chen, attorney-in-fact 2020-01-17